<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02829931</url>
  </required_header>
  <id_info>
    <org_study_id>MCC-18661</org_study_id>
    <nct_id>NCT02829931</nct_id>
  </id_info>
  <brief_title>Hypofractionated Stereotactic Irradiation With Nivolumab in Patients With Recurrent High Grade Gliomas</brief_title>
  <official_title>Phase I Trial of Hypofractionated Stereotactic Irradiation (HFSRT) Combined With Nivolumab in Patients With Recurrent High Grade Gliomas</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>H. Lee Moffitt Cancer Center and Research Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>H. Lee Moffitt Cancer Center and Research Institute</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main purpose of this study is to evaluate the safety and tolerability of nivolumab, given
      in combination with hypofractionated stereotactic re-irradiation of recurrent high grade
      gliomas.
    </textblock>
  </brief_summary>
  <overall_status>Suspended</overall_status>
  <why_stopped>
    Enrollment on hold per industry sponsor
  </why_stopped>
  <start_date type="Actual">August 9, 2016</start_date>
  <completion_date type="Anticipated">April 2020</completion_date>
  <primary_completion_date type="Anticipated">April 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants with Treatment Related Adverse Events</measure>
    <time_frame>Up to 24 months</time_frame>
    <description>Safety and tolerability of nivolumab, given in combination with hypofractionated stereotactic re-irradiation of recurrent high grade gliomas.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Response Rate</measure>
    <time_frame>Up to 36 months</time_frame>
    <description>All participants will receive efficacy assessments with brain MRI at time points specified in Trial Flow Chart. Cases of suspected radiologic disease progression will be confirmed by an MRI performed approximately 8 weeks after the initial radiological assessment of progression. Immunotherapy Response Assessment in Neuro-Oncology (iRANO) and Response Assessment Criteria for High-Grade Gliomas (RANO Criteria) will be used for assessing the response to study treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS) Rate at 6 Months</measure>
    <time_frame>6 months</time_frame>
    <description>OS, utilizing 95% confidence interval (95%CI).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS) Rate at 9 Months</measure>
    <time_frame>9 months</time_frame>
    <description>OS, utilizing 95% confidence interval (95%CI).</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">26</enrollment>
  <condition>Malignant Glioma</condition>
  <arm_group>
    <arm_group_label>Combination Therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Safety Cohort: The first 6 participants will receive Nivolumab only to start.
Dose Expansion Cohort: All 26 participants will be treated with Hypofractionated Stereotactic Irradiation (HFSRT), followed by Nivolumab.</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Hypofractionated Stereotactic Irradiation</intervention_name>
    <description>Hypofractionated Stereotactic Irradiation (HFSRT) prior to nivolumab.</description>
    <arm_group_label>Combination Therapy</arm_group_label>
    <other_name>HFSRT</other_name>
    <other_name>radiation therapy</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nivolumab</intervention_name>
    <description>Nivolumab intravenously (IV): 240 mg every (q) 2 weeks x 4 months followed by 480 mg q 4 weeks.</description>
    <arm_group_label>Combination Therapy</arm_group_label>
    <other_name>OPDIVO</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically confirmed diagnosis of World Health Organization (WHO) Grade III or IV
             malignant glioma.

          -  Documented recurrence by diagnostic biopsy or contrast enhanced magnetic resonance
             imaging (MRI) performed within 28 days of entry in to the trial as per Response
             Assessment in Neuro-Oncology (RANO) criteria.

          -  Maximum diameter of enhancing tumor (target lesion) should be ≤ 4 cm.

          -  An interval of at least 6 months after the end of prior radiation therapy is required
             unless there is a new recurrence outside of the previous radiotherapy treatment field.

          -  Previous first line treatment with at least standard dose of radiotherapy (total dose
             ≥ 54 Gy) and temozolomide

          -  An interval of ≥ 4 weeks since surgical resection prior to study treatment.

          -  An interval of ≥ 4 weeks after the last administration of any investigational agent,
             bevacizumab, or prior cytotoxic therapy.

          -  ≥18 years of age on day of signing informed consent.

          -  Karnofsky performance status of 70 or higher.

          -  Demonstrate adequate organ function. All screening labs should be performed within 14
             days of treatment initiation.

          -  Resting baseline O2 saturation by pulse oximetry of ≥ 92% at rest.

          -  Must have recovered from the toxic effects of prior therapies (≤ Grade 1).

          -  Willing and able to provide written informed consent for the trial.

          -  Life expectancy ≥ 12 weeks

          -  Women of childbearing potential (WOCBP) should have a negative urine or serum
             pregnancy within 72 hours prior to receiving the first dose of study medication. If
             the urine test is positive or cannot be confirmed as negative, a serum pregnancy test
             will be required. WOCBP should be willing to use 2 methods of birth control or be
             surgically sterile, or abstain from heterosexual activity for the course of the study
             through 120 days after the last dose of study medication.

          -  Males should agree to use an adequate method of contraception starting with the first
             dose of study therapy through 120 days after the last dose of study therapy.

        Exclusion Criteria:

          -  Has more than three recurrences of high grade glioma. Previous recurrences of low
             grade glioma is not considered.

          -  Has received re-radiation to recurrent disease (other than standard frontline adjuvant
             radiation therapy).

          -  Recurrent tumors near the brainstem and optic chiasm must not have received prior
             radiation therapy.

          -  Has infratentorial, or leptomeningeal evidence of recurrent disease.

          -  Has recurrent or persistent tumor (enhancing area) greater than 4 cm in maximum
             diameter.

          -  Has prior treatment with Gliadel unless it was administered as first line treatment
             and at least 3 months prior to study treatment.

          -  Is unable (due to existent medical condition) or unwilling to have a contrast enhanced
             MRI of brain.

          -  Is currently participating in or has participated in a study of an investigational
             agent or using an investigational device within 4 weeks of the first dose of
             treatment.

          -  Has a diagnosis of immunodeficiency or is receiving systemic immunosuppressive therapy
             within 7 days prior to the first dose of trial treatment. Physiologic doses of steroid
             therapy (≤ 10 mg/day prednisone equivalents) is allowed.

          -  Has had a prior chemotherapy, targeted small molecule therapy, or monoclonal antibody
             within 4 weeks prior to study Day 1 or who has not recovered (i.e., ≤ Grade 1 or at
             baseline) from adverse events due to agents administered more than 4 weeks earlier.

          -  Has a known additional malignancy that is progressing or requires active treatment.
             Exceptions include basal cell carcinoma of the skin, squamous cell carcinoma of the
             skin, or in situ cervical cancer that has undergone potentially curative therapy.

          -  Has an active autoimmune disease requiring systemic treatment within the past 3 months
             or a documented history of clinically severe autoimmune disease, or a syndrome that
             requires systemic steroids or immunosuppressive agents. Potential participants with
             vitiligo or resolved childhood asthma/atopy would be an exception to this rule.
             Potential participants that require intermittent use of bronchodilators or local
             steroid injections would not be excluded from the study. Potential participants with
             hypothyroidism stable on hormone replacement or Sjorgen's syndrome will not be
             excluded from the study.

          -  Has evidence of interstitial lung disease or active, non-infectious pneumonitis.

          -  Has an active infection requiring systemic therapy.

          -  Had major surgical procedure, open biopsy, or significant traumatic injury within 28
             days prior to day 1 of treatment on study.

          -  Requires escalating or chronic supraphysiologic doses of corticosteroids (&gt; 10 mg/day
             prednisone equivalents).

          -  Has a history or current evidence of any condition, therapy, or laboratory abnormality
             that might confound the results of the trial, interfere with participation for the
             full duration of the trial, or is not in the best interest of the participant, in the
             opinion of the treating investigator.

          -  Has known psychiatric or substance abuse disorders that would interfere with
             cooperation with the requirements of the trial.

          -  Is pregnant or breastfeeding, or expecting to conceive or father children within the
             projected duration of the trial, starting with the pre-screening or screening visit
             through 120 days after the last dose of trial treatment.

          -  Has received prior therapy with an anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CD137, or
             anti-Cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) antibody (including
             ipilimumab or any other antibody or drug specifically targeting T-cell co-stimulation
             or checkpoint pathways).

          -  Has a known history of Human Immunodeficiency Virus (HIV) (HIV 1/2 antibodies).

          -  Has known active Hepatitis B (e.g., HBsAg reactive) or Hepatitis C Virus (HCV) (e.g.,
             HCV RNA [qualitative] is detected).

          -  Has received a live vaccine within 30 days prior to the first dose of trial treatment.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Solmaz Sahebjam, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>H. Lee Moffitt Cancer Center and Research Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>H. Lee Moffitt Cancer Center and Research Institute</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ohio State University Comprehensive Cancer Center</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://moffitt.org/clinical-trials-research/</url>
    <description>Moffitt Cancer Center Clinical Trials website</description>
  </link>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 8, 2016</study_first_submitted>
  <study_first_submitted_qc>July 8, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 12, 2016</study_first_posted>
  <last_update_submitted>May 10, 2018</last_update_submitted>
  <last_update_submitted_qc>May 10, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 11, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>recurrent glioma</keyword>
  <keyword>high grade glioma</keyword>
  <keyword>head and neck disease</keyword>
  <keyword>grade III glioma</keyword>
  <keyword>grade IV glioma</keyword>
  <keyword>radiation therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glioma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nivolumab</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

